Shaanxi Aoxing Pharmaceutical Co., Ltd. Renewed its GMP Certification
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its variable interest entity in China, Shaanxi Aoxing Pharmaceutical Co., Ltd. ("Aoxing"), has renewed its Good Manufacturing Practices (GMP) certificate and Pharmaceutical Production License. The Company received the renewed GMP certificate evidencing compliance on January 31, 2018.
Mr. Wang Ronghua, the Chairman of Biostar, stated: "The Company is pleased to have completed the GMP certification inspection and approval process. We expect that the GMP certification renewal will allow us to resume our production in the coming months as the Company makes preparations to carry on with the implementation of its business plan and growth objectives."
Looking for chemical products? Let suppliers reach out to you!
2026-07-12
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The project of fine chemicals with 4000 t/a Tebuconazole and Diflufenican is to be built
-
Pharmaconex 2022
-
CPHI Korea 2022
-
Shandong Pharmaceutical Companies Grab Over $1 Billion of Antithrombotic Drugs for The First Imitation, Original Research Drugs Soared 5527%
-
ECHEMI International Trade Business School Bangladesh Pharmaceutical Summary
-
Industrialization Progress of genetically modified pharmaceutical products
-
2022 Top 50 Global Pharmaceutical Companies Released! Pfizer Returns to NO.1, Kexing Counterattack First on the List
-
Pharmaceutical and Health Industry Special Study - The Arrival of New Opportunities
-
Accelerate Technological Breakthroughs in Product Innovation and Promote the Industrialization and Application of Innovative Drugs
-
The Rare Disease Market Continues to Heat Up. How Will The Global Top 10 Pharmaceutical Companies by Revenue in 2021 be Deployed?
Recommend Reading
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
Loose Supply, Weak and Declining Aniline Market (Dec. 8–Dec. 12)
-
EFSA Unable to Conclude on Full-Scope Safety of Genetically Modified Oilseed Rape LBFLFK
-
China's Marine Fuel Market Sees Volatile Rise in September
-
Costs Decline, DOP Prices Retreat from High Levels This Week
-
EFSA Evaluates Safety of Triacylglycerol Lipase from Ruminant Pregastric Tissue